RVNC Live signals | Maximize Profits with Getagraph.com

BUY 88434 min ago

@ $5.59

Issued: 14 Feb 2024 @ 13:54

Return: -29.01%

Previous signal: Feb 14 - 09:30

Previous signal: Sell

Return: 3.36 %

Live Chart Being Loaded With Signals

Commentary (15 Apr 2024 @ 16:00):

Stats
Today's Volume	2.11M
Average Volume	1.76M
Market Cap	413.74M
EPS	$0 ( 2024-02-28 )
Next earnings date	( $-0.660 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.040
ATR14	$0.00700 (0.18%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-15	Sjuts Dustin S	Sell	2 967	Common Stock
2024-03-18	Sjuts Dustin S	Sell	9 211	Common Stock
2024-03-15	Moxie Dwight	Sell	3 269	Common Stock
2024-03-18	Moxie Dwight	Sell	8 125	Common Stock
2024-03-15	Schilke Tobin	Sell	3 822	Common Stock

INSIDER POWER
64.42
Last 97 transactions
Buy: 2 720 068 \| Sell: 627 941

Volume Correlation

Long: -0.26 (neutral)

Short: 0.33 (neutral)

Signal:(27.21) Neutral

Revance Therapeutics Inc Correlation

10 Most Positive Correlations
SYKE	0.944
SPRB	0.923
BRACU	0.922
XLRN	0.921
PIRS	0.918
ATCX	0.918
MESA	0.915
VRME	0.915
JFIN	0.913
OVID	0.907

10 Most Negative Correlations
AHPI	-0.934
TUEM	-0.902
VERA	-0.881
ARDS	-0.865
CYTO	-0.86
NAKD	-0.852
LCAP	-0.85
CFV	-0.844
JRJC	-0.843
APM	-0.837

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Revance Therapeutics Inc Correlation - Currency/Commodity

-0.59
( weak negative )

-0.70
( moderate negative )

0.00
( neutral )

-0.55
( weak negative )

0.00
( neutral )

0.81
( strong )

Revance Therapeutics Inc Financials

Annual	2023
Revenue:	$234.04M
Gross Profit:	$145.98M (62.38 %)
EPS:	$-3.83

Q4	2023
Revenue:	$69.80M
Gross Profit:	$50.91M (72.94 %)
EPS:	$-0.620

Q3	2023
Revenue:	$56.78M
Gross Profit:	$37.36M (65.81 %)
EPS:	$-1.630

Q2	2023
Revenue:	$58.13M
Gross Profit:	$36.83M (63.35 %)
EPS:	$-0.800

Financial Reports:

No articles found.

Revance Therapeutics Inc

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing DaxibotulinumtoxinA in preclinical trial for the treatment of migraine, as well as a topical program for various indications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.